Management of psychosis in Parkinson's disease

International Journal of Clinical Practice

Volumn 57, Issue 4, 2003, Pages 295-300

  D'Souza, Charles ^a   Gupta, A ^b   Alldrick, M D ^c   Sastry, B S D ^d  

^a Rookwood Hospital   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c WHITCHURCH HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CATECHOL METHYLTRANSFERASE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CIMETIDINE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; ORPHENADRINE; OXYBUTYNIN; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SELEGILINE; SPASMOLYTIC AGENT; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE;

AGRANULOCYTOSIS; CONFUSION; DELIRIUM; DISABILITY; DISEASE EXACERBATION; DROWSINESS; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERSALIVATION; INDEPENDENCE; LONG TERM CARE; MOTOR DYSFUNCTION; NURSING HOME; ORTHOSTATIC HYPOTENSION; PARANOIA; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SYMPTOMATOLOGY; VISUAL HALLUCINATION;

ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; PARKINSON DISEASE; PSYCHOTIC DISORDERS; SEROTONIN ANTAGONISTS;

EID: 0038202928     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease: a community based study. Arch Neurol 1999; 56: 595-601.
2. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733-745.
3. Factor SA, Molho ES, Podskalny G et al. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995; 65: 115-138.
4. Melamed E, Friedberg G, Zoldan J. Psychosis: impact on the patient and family. Neurology 1999; 52(suppl 3): S14-S16.
5. Ellgring JH. Depression, psychosis, and dementia: impact on the family. Neurology 1999; 52(suppl 3): S17-S20.
6. Factor SA, Molho ES. Emergency department presentations of patients with Parkinson's disease. Am J Emerg Med 2000; 18: 209-215.
7. Juncos JL. Management of psychotic aspects of Parkinson's disease. J Clin Psychiatry 1999; 60(suppl 8): 42-53.
8. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based prospective study. J Am Geriatr Soc 2000; 48: 938-942.
9. Goetz CG, Stebins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43: 2227-2229.
10. Goetz CG, Stebins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45: 669-676.
11. Henderson MJ, Mellers JDC. Psychosis in Parkinson's disease: 'between a rock and a hard place'. Int Rev Psychiatry 2000; 12: 319-334.
12. Wolters EC, Berendse HW. Management of psychosis in Parkinson's disease. Curr Opin Neurol 2001; 14: 499-504.
13. Giladi N, Treves TA, Paleacu D et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Trans 2000; 107: 59-71.
14. Friedman JH. The management of levodopa psychosis. Clin Neuropharmacol 1991; 14: 283-295.
15. Korczyn AD. Hallucinations in Parkinson's disease. Lancet 2001; 358: 1031-1032.
16. Inzelburg R, Kippervasser S, Korczyn A. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 533-535.
17. Nausieda PA, Werner WJ, Kaplan LR et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of levodopa psychosis. Clin Neuropharmacol 1982; 5: 183-194.
18. Litvan I, MacIntyre A, Goetz CG et al. Accuracy of the clinical diagnosis of Lewy body disease, Parkinson's disease and dementia with Lewy bodies: a clinicopathologic study. Neurology 1998; 55: 969-978.
19. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug induced hallucinations in parkinsonian patients. Neurology 1998; 51: 811-814.
20. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56(suppl 5): S1-S88.
21. Saint-Cyr J, Taylor A, Lang A. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993; 43(suppl 6): S47-S52.
22. Frankel J, Lees A, Kempster P et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 96-101.
23. Ellis C, Lemmens Parker J. Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment. Neurology 1995; 45(suppl 4): A251.
24. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal. JAMA 1985; 254: 2792-2795.
25. Joseph CL, Siple J, McWhorter K et al. Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports. J Am Geriatr Soc 1995; 43: 47-50.
26. Friedman JH. Drug holidays in the treatment of Parkinson's disease: a brief review. Arch Intern Med 1985; 145: 913-915.
27. Mayeux R, Stern Y, Mulvey K et al. Reappraisal of temporary levodopa withdrawal ('drug holidays') in Parkinson's disease. N Engl J Med 1985; 313: 724-728.
28. Bhatia K Brooks DJ, Burn DJ et al. Updated guidelines for the management of Parkinson's disease. Parkinson's Disease Consensus Working Group. Hosp Med 2001; 62: 456-470.
29. Kalish SC, Bohn RL, Mogun H et al. Antipsychotic prescribing patterns and the treatment of extrapyramidal symptoms in older people. J Am Geriatr Soc 1995; 43: 967-973.
30. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 201-211.
31. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pk 1 values. J Pharmacol Exp Ther 1989; 251: 238-246.
32. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristic? A review of the evidence. Neuropharmacology 1998; 18: 63-101.
33. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757-763.
34. The French Clozapine Parkinson Study Group. Clozapine in drug induced psychosis in Parkinson's disease. Lancet 1999; 353: 2041-2042.
35. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55: 789-794.
36. Factor SA, Friedman JH, Lannon MC et al. The Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12-week open label extension in the PSYCLOPS trial. Mov Disord 2001; 16: 135-139.
37. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12: 483-496.
38. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990; 5: 225-229.
39. Friedman JH, Koller WC, Lannon MC et al. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 1997; 4: 1077-1081.
40. Alvir JMA, Lieberman JA, Safferman AZ. Clozapine induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-167.
41. Honigfeld G, Arellano F, Sethi J et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59: 3-7.
42. Cummings JL. Managing psychosis in patients with Parkinson's disease. N Engl J Med 1999; 340: 801-803.
43. Rabinstein AA, Shulman LM. Management of behavioral and psychiatric problems in Parkinson's disease. Parkinsonism Relat Disord 2000; 7: 41-50.
44. Wolters EC. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology 1999; 52(suppl 3): S10-S13.
45. Rascol O, Goetz C, Koller W et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359: 1589-1598.
46. Parsa MA, Bastini B: Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998; 10: 216-219.
47. Fernandez HH, Lannon MC, Friedman JH, Abbott BP. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 579-581.
48. Dewey RB Jr, O'Suilleabhain PE. Treatment of drug induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 2000; 55: 1753-1754.
49. Menza MMA, Palermo B, Mark M. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann Clin Psychiatry 1999; 11: 141-144.
50. Matheson AJ, Lamb HM. Quetiapine: a review of its clinical potential in the management of psychotic symptoms in Parkinson's disease. CNS Drugs 2000; 14: 157-172.
51. Marsh L, Lyketsos C, Reich SG. Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia. Psychosomatics 2001; 42: 477-481.
52. Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PLM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47: 1085-1087.
53. Aarsland D, Larsen JP, Lim NG, Tandberg E. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci 1999; 11: 392-394.
54. Molho ES, Factor SA. Worsening of motor features of Parkinsonism with olanzapine. Mov Disord 1999; 14: 1014-1016.
55. Leucht S. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients (letter). Neurology 2001; 57: 747.
56. Meco G, Allessandria A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994; 343: 1370-1371.
57. Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000; 15: 1230-1237.
58. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000; 15: 301-304.
59. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000; 12: 364-369.
60. Ford B, Lynch TC, Greene P. Risperidone in Parkinson's disease (letter). Lancet 1994; 344: 681.
61. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556-559.
62. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999; 52: 782-785.
63. Knable MB, Heinz A, Raedler T, Weinberger DR. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res 1997; 75: 91-100.
64. Workman RH Jr, Orengo CA, Bakey AA et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1997; 9: 594-597.
65. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3-receptor antagonist. Neurology 1995; 45: 1305-1308.
66. Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa psychosis. Neurology 1996; 47: 1608-1609.
67. McKeith IG, Grace JB, Walker Z et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000; 15: 387-392.
68. Skjerve A, Nygaard HA. Improvement in sundowning in dementia with Lewy bodies after treatment with donezepil. Int J Psychiatry 2000; 15: 1147-1151.
69. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16: 1171-1174.
70. Fabbrini G, Barbanti P, Aurilia C et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurolog Sci 2002; 23: 41-43.
71. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002; 25: 107-110.